Hikma Pharmaceuticals PLC (HKMPY)

USD 48.77

(0.0%)

Market Cap (In USD)

5.4 Billion

Revenue (In USD)

2.87 Billion

Net Income (In USD)

190 Million

Avg. Volume

141.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
44.79-55.56
PE
-
EPS
-
Beta Value
0.435
ISIN
US4312881091
CUSIP
431288109
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Riad Ali Mishlawi
Employee Count
-
Website
https://www.hikma.com
Ipo Date
2012-02-07
Details
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.